Aix-en-Provence

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Retrieved on: 
Wednesday, April 10, 2024
Wealth, Aix-en-Provence, TP ICAP, TP, Ticker, Medtech, Security (finance)

Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by Gilbert Dupont – Société Générale Group.
  • Aix-en-Provence, 4 April 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Gilbert Dupont – Société Générale Group has initiated coverage of its stock.
  • Gilbert Dupont – Société Générale Group began covering the stock with a study entitled "Un pour tous, tous pour un" ("one for all and all for one"), published on 3 April 2024.
  • In this study, Gilbert Dupont – Société Générale Group recommended buying the stock, with a target price of €3.30, representing a potential upside of 89% compared with the closing price on 2 April 2024.

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Retrieved on: 
Wednesday, April 10, 2024
TP, Wealth, Aix-en-Provence, Ticker, Medtech

Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by TP ICAP Midcap.
  • Aix-en-Provence, 28 March 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that TP ICAP Midcap has initiated coverage of its stock.
  • TP ICAP Midcap began covering the stock with a study entitled "Du baume au coeur" ("Heart-Warming"), published on 27 March 2024.
  • This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities, Kepler Cheuvreux, and Portzamparc BNP Paribas Group.

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
Wednesday, March 13, 2024
Mitral regurgitation, Ticker, Aix-en-Provence, Doctor of Philosophy, MD, Overalls, Physiology, Hospital, Minerva, Risk, Tricuspid valve, Mayo Clinic, Clinical professor, Death, American College, Medtech, Mitral valve, Patient, Interventional cardiology

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.

Retrieved on: 
Tuesday, January 30, 2024
Patient, LCEA, Partnership, Urinary incontinence, Artus, Euronext Paris, Ticker, Medtech, Shareholder, Medicine, Aix-en-Provence, FDA, Mitral valve, Surgeon, Security (finance)

Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.

Key Points: 
  • Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.
  • Key shareholders provide bridge to continue exploring options to secure long term financing.
  • Aix-en-Provence, 29 January 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specialising in the international development and industrialisation of innovative medical prostheses, today announced the closing of a €3.5 million bridge financing with its key existing shareholders.
  • Following this transaction, Affluent Medical share capital now consists of 33.145.236 shares, each with a nominal value of €0.10.

Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.

Retrieved on: 
Wednesday, January 17, 2024
Tricuspid valve, Patient, Myocardial infarction, Mitral valve, Optimization, Ticker, Food, Medtech, Aix-en-Provence, FDA, Letter, Data, File, Medical device

Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.

Key Points: 
  • Affluent Medical : Pre-submission dossier for the 510(k) of medical device KaliosTM filed with FDA for review.
  • Assessments of the FDA review to be discussed in a meeting towards the end of the first quarter.
  • End of Q1 2024, Affluent Medical will schedule a meeting with the FDA to discuss their substantive feedback on the pre-submission dossier.
  • Affluent Medical believes that Kalios™ could avoid further interventions for potentially 30-40% of patients over five-years.

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Retrieved on: 
Saturday, December 30, 2023
Neurostimulation, EAU, Woman, Medtech, Research, Male, Hope, Nursing, European, Health, Ageing, Urinary incontinence, Mental health, Anxiety, Incontinence, Prostate, Pathology, Aix-en-Provence, Patient, Ticker, Artus, Disorder, Female, Pharmaceutical industry

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Key Points: 
  • Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
  • Artus is an innovative device adapted for the treatment of incontinence in women and men.
  • Aix-en-Provence, 6 December 2023 – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specialising in the international development and industrialisation of innovative medical prostheses, is announcing the start of the European pilot study, Dry, with its Artus medical device for the treatment of urinary incontinence.
  • Publication of an international study by the European Association of Urology on the economic consequences of urinary incontinence in Europe.

Transformative Artistry by Vietnamese Artist Tia-Thuy Nguyen: 'Flower of Life' Blooms at Château La Coste

Retrieved on: 
Monday, November 20, 2023
Primary energy, Woman, Observation, Creativity, National academy, Regeneration, Flower, Multimedia, Nature, Lacoste, Exhibition, Aix-en-Provence, Fine art, Flower of Life, Art, Life, Sunlight, Architecture

Through the eyes of artist Tia-Thuy Nguyen, the dead tree is the beginning of a new chapter.

Key Points: 
  • Through the eyes of artist Tia-Thuy Nguyen, the dead tree is the beginning of a new chapter.
  • Tia-Thuy Nguyen exhibiting her artwork at Château La Coste for the third time demonstrates recognition and appreciation for her work and influence.
  • Château La Coste is an art garden located in the Aix-en-Provence region of southern France.
  • "Flower of Life" exhibition by artist Tia-Thuy Nguyen will open from 18th November 2023 to 30th January 2024, at Château La Coste, 2750 Route De La Cride, 13610 Le Puy-Sainte-Réparade, France.

Transformative Artistry by Vietnamese Artist Tia-Thuy Nguyen: 'Flower of Life' Blooms at Château La Coste

Retrieved on: 
Monday, November 20, 2023
Primary energy, Woman, Observation, Creativity, National academy, Regeneration, Flower, Nature, Lacoste, Exhibition, Aix-en-Provence, Fine art, Flower of Life, Art, Life, Sunlight, Architecture

Through the eyes of artist Tia-Thuy Nguyen, the dead tree is the beginning of a new chapter.

Key Points: 
  • Through the eyes of artist Tia-Thuy Nguyen, the dead tree is the beginning of a new chapter.
  • Tia-Thuy Nguyen exhibiting her artwork at Château La Coste for the third time demonstrates recognition and appreciation for her work and influence.
  • Château La Coste is an art garden located in the Aix-en-Provence region of southern France.
  • "Flower of Life" exhibition by artist Tia-Thuy Nguyen will open from 18th November 2023 to 30th January 2024, at Château La Coste, 2750 Route De La Cride, 13610 Le Puy-Sainte-Réparade, France.

Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.

Retrieved on: 
Thursday, December 14, 2023
Ukrsibbank BNP Paribas Group, ISIN, China Investment Securities, Regulatory News Service, Medtech, BNP Paribas, Wealth, Aix-en-Provence, Kepler Cheuvreux, Security (finance), Portzamparc

Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.

Key Points: 
  • Affluent Medical announces coverage initiation of its stock by Portzamparc – Groupe BNP Paribas.
  • Aix-en-Provence, November 27, 2023 – 7:30 am CEST- Affluent Medical (ISIN code: FR0013333077 – ticker: AFME), a French clinical-stage MedTech company specializing in the international development and industrialization of innovative medical prostheses, announces today that Portzamparc - Groupe BNP Paribas has initiated coverage of its stock.
  • Portzamparc - BNP Paribas Group began covering the stock with a study entitled "Au plus proche de votre coeur" ("Closer to your heart"), published on November 24, 2023.
  • This initiation completes the coverage of Affluent Medical’s stock and adds to the financial analyst consensus alongside Invest Securities and Kepler Cheuvreux.

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, Regulatory News Service, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.